title: Percutaneous coronary intervention in anticoagulated patients via radial artery access.
abstract: OBJECTIVE
  To assess safety and feasibility of using radial artery access for percutaneous coronary intervention (PCI) in patients on oral anticoagulation without interrupting therapy.
  
  
  BACKGROUND
  The radial artery approach for PCI is intuitively attractive for patients receiving chronic oral anticoagulation with vitamin K antagonists (VKAs) but little data exist concerning feasibility or safety of this approach in this population. The main advantage of this strategy would be to avoid bridging therapy with heparin that increases risk of thrombotic and bleeding events.
  
  
  METHODS
  In this prospective observational study, 50 consecutive patients referred for coronary angiography underwent PCI without interrupting oral anticoagulant therapy. The main outcome measures were bleeding and thrombotic complications.
  
  
  RESULTS
  The indications for permanent oral anticoagulation were as follows: atrial fibrillation in 62%, mechanical prosthesis in 24%, and venous thromboembolism in 14%. Seventy-two percent were elective cases and 28% presented with acute coronary syndromes. PCI was performed with an INR range of 1.4-3.4 with mean of 2.2 +/- 0.6. Seventy-six percent of the patients were on dual antiplatelet therapy before the procedure. No thrombotic events or excess bleeding were observed at 1 month. Only one patient had a minor hemorrhage 8 days after procedure.
  
  
  CONCLUSIONS
  This series suggests that for patients treated with VKAs, the use of radial artery access is feasible and safe for PCI on dual antiplatelet therapy without interrupting oral anticoagulant treatment.
authors.affiliation: Department of Cardiology, Institut de Cardiologie - GH Pitié-Salpétrière, AP-HP, Université Pierre et Marie Curie, Paris, France. gerard.helft@psl.aphp.fr
authors.forename: Gérard
authors.initials: G
authors.lastname: Helft
authors.forename: Grégoire
authors.initials: G
authors.lastname: Dambrin
authors.forename: Azfar
authors.initials: A
authors.lastname: Zaman
authors.forename: Claude
authors.initials: C
authors.lastname: Le Feuvre
authors.forename: Olivier
authors.initials: O
authors.lastname: Barthélémy
authors.forename: Farzin
authors.initials: F
authors.lastname: Beygui
authors.forename: Xavier
authors.initials: X
authors.lastname: Favereau
authors.forename: Jean-Philippe
authors.initials: JP
authors.lastname: Metzger
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000379:methods*; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000000981:diagnostic imaging / Q000628:therapy*; D004334:Drug Administration Schedule; D004739:England; D005240:Feasibility Studies; D005260:Female; D005602:France; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011446:Prospective Studies; D017534:Radial Artery; D013927:Thrombosis / Q000209:etiology; D013997:Time Factors; D016896:Treatment Outcome; D014812:Vitamin K / Q000037:antagonists & inhibitors
chemical_list: D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D014812:Vitamin K